Shattuck Labs, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Shattuck Labs, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $80.20M.
- Shattuck Labs, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $20.56M.
- Shattuck Labs, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $44.48M.
- Shattuck Labs, Inc. stock issued during period, value, new issues for fiscal 2025 was $44.48M.
- Shattuck Labs, Inc. stock issued during period, value, new issues for fiscal 2020 was $213.53M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $80.20M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $20.56M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $44.48M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $44.48M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $4.65M 10-Q · filed 2024-05-02 | |
| 2020-12-31 | $213.53M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |